Prescribing Data for Multiple Sclerosis

NHS Bassetlaw Clinical Commissioning Group Nid oedd gan y wybodaeth y gofynnwyd amdani.

Dear Bassetlaw Clinical Commissioning Group,

The MS Society is collecting the following information from every CCG in the Country to help us understand the national picture better in relation to prescribing. To help us with our research, we are requesting the following information through the Freedom of Information Act.
1. How many people with MS in your CCG (including the source for this number):
a. Relapsing-Remitting MS
b. Primary Progressive MS
c. Secondary Progressive MS
d. Benign MS
e. Unconfirmed Type
2. The percentage of each of 1a, 1b, 1c, 1d, and 1e, who receive an annual review by a healthcare professional with expertise in MS, and it’s complications (NICE guidelines (CG 186).

3. The current waiting times targets for accessing an appointment with a Consultant Neurologist with MS expertise for:

a. New appointments
b. Follow up appointments

4. The number of Individual Funding Requests (IFRs) received for each of the below treatments

5. The number of people with MS currently being prescribed the following licensed treatments for multiple sclerosis
a. Avonex (Beta interferon – 1a)
b. Aubagio® (Teriflunomide)
c. Betaferon (Interferon beta 1b)
d. Botox (Botulinum toxin)
e. Copaxone (Glatiramer Acetate)
f. Extavia (Beta interferon – 1b)
g. Fampyra® (Fampridine)
h. Gilenya (Fingolimod)
i. Lemtrada (Alemtuzumab)
j. Plegridy (Peginterferon beta 1a)
k. Rebif® (Beta interferon – 1a)
l. Sativex (Nabiximols)
m. Tecfidera (Dimethyl fumarate)
n. Tysabri (Natalizumab)

Yours faithfully,

Liz Whilde
MS Society Regional External Relations Officer East Midlands

FOIRequests (NHS BASSETLAW CCG), NHS Bassetlaw Clinical Commissioning Group

Dear Liz

FOI_16_25

Thank you for your recent request for information. This request was received by NHS Bassetlaw CCG on the 3rd February 2016; we will respond to you no later than 2nd March 2016 (20 working days).

Regards

Sarah

Sarah Beard
Assurance & Engagement Officer
NHS Bassetlaw CCG
Retford Hospital
North Road
DN22 7XF

01777 863308
www.bassetlawccg.nhs.uk

dangos adrannau a ddyfynnir

FOIRequests (NHS BASSETLAW CCG), NHS Bassetlaw Clinical Commissioning Group

 

 

Dear Liz

 

FOI_16_25

 

Thank you for your recent request under the Freedom of Information Act. 
Please see our responses highlighted below;

 

The MS Society is collecting the following information from every

     CCG in the Country to help us understand the national picture

     better in relation to prescribing. To help us with our research, we

     are requesting the following information through the Freedom of

     Information Act.

     1. How many people with MS in your CCG (including the source for

     this number):

     a. Relapsing-Remitting MS

     b. Primary Progressive MS

     c. Secondary Progressive MS

     d. Benign MS

     e. Unconfirmed Type

     2. The percentage of each of 1a, 1b, 1c, 1d, and 1e, who receive an

     annual review by a healthcare professional with expertise in MS,

     and it’s complications (NICE guidelines (CG 186).

 

The CCG does not hold this information, therefore we suggest that you
source this from the Acute provider, Doncaster and Bassetlaw Hospitals NHS
Foundation Trust

    

     3. The current waiting times targets for accessing an appointment

     with a Consultant Neurologist with MS expertise for:

    

     a. New appointments

     b. Follow up appointments

 

The CCG does not hold this information, therefore we suggest that you
source this from the Acute provider, Doncaster and Bassetlaw Hospitals NHS
Foundation Trust

    

     4. The number of Individual Funding Requests (IFRs) received for

     each of the below treatments

    

The CCG does not hold this information, therefore we suggest that you
contact Yorkshire & Humber Commissioning Support Unit (CSU)

 

     5. The number of people with MS currently being prescribed the

     following licensed treatments for multiple sclerosis

     a. Avonex (Beta interferon – 1a)

     b. Aubagio® (Teriflunomide)

     c. Betaferon (Interferon beta 1b)

     d. Botox (Botulinum toxin)

     e. Copaxone (Glatiramer Acetate)

     f. Extavia (Beta interferon – 1b)

     g. Fampyra® (Fampridine)

     h. Gilenya (Fingolimod)

     i. Lemtrada (Alemtuzumab)

     j. Plegridy (Peginterferon beta 1a)

     k. Rebif® (Beta interferon – 1a)

     l. Sativex (Nabiximols)

     m. Tecfidera (Dimethyl fumarate)

     n. Tysabri (Natalizumab)

    

The CCG does not hold this information, NHS Business Services authority
may hold this.

 

I trust this fulfils your requirements.

 

Regards

 

Sarah

 

Sarah Beard

Assurance & Engagement Officer

NHS Bassetlaw CCG

Retford Hospital

North Road

DN22 7XF

 

01777 863308

[1]www.bassetlawccg.nhs.uk

 

 

 

 

 

dangos adrannau a ddyfynnir

Dear FOIRequests (NHS BASSETLAW CCG),

Many thanks for your response

Yours sincerely,

Liz Whilde